首页> 生物试剂> 抗体和免疫分析> ELISA> Certolizumab ELISA Kit,96T,DF879028-96T,Abinscience

Certolizumab ELISA Kit,96T,DF879028-96T,Abinscience

销售价: ¥ 6756.00 / 件
在线询价
优    惠: 请询价
订货号 0BC4759
品牌型号 Abinscience DF879028-96T
库存 有库存
最小订货量 1件
联系我们
  • 400-920-3909
AbinscienceELISA其它型号产品
  • 商品介绍
  • 规格参数
  • 包装参数
产品介绍 Product Description
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human TNFa has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Certolizumab in the sample competitively binds to the pre-coated protein with biotin-labeled Certolizumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Certolizumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
技术参数 Specifications
Stability and StorageWhen the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.
Detection methodColorimetric
Sample typePlasma, Serum
Assay typeQuantitative
Sensitivity329.66 ng/mL
Range468.75 - 30,000 ng/mL
Recovery80-120%
BackgroundCertolizumab pegol is a recombinant, humanized F(ab)’ fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It does not contain an FC region and therefore does not cause antibody-dependent cell-mediated or complement-dependent cytotoxicity as described for infliximab, etanercept, and adalimumab. Another difference is that certolizumab pegol preferentially penetrates inflamed tissue compared to noninflamed tissue, and does so to a greater extent than adalimumab or infliximab. It is directed against soluble and membrane-associated human TNF-α and was approved for the treatment of Crohn’s disease that does not respond to conventional therapy in 2008 and for RA in 2009.
Alternative NamesCDP870, PHA-738144, Certolizumab pegol, CAS: 428863-50-7
Shipping2-8 ℃
SpecificationsCertolizumab
NoteFor Research Use Only.
长度(mm)
宽度(mm)
高度(mm)
重量(kg)
猜你喜欢

在线
客服

在线客服服务时间:09:00-18:00

客服
热线

400-920-3909
客服服务热线 周一至周五(09:00-18:00)

微信
咨询

微信小程序 7X24小时在线咨询